TRAIL receptor I (<it>DR4</it>) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients

TRAIL receptor I (<it>DR4</it>) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients

<p>Abstract</p> <p>Background</p> <p>Tumour surveillance via induction of TRAIL-mediated apoptosis is a key mechanism, how the immune system prevents malignancy. To determine if gene variants in the TRAIL receptor I (<it>DR4</it>) gene affect the risk of hep...

Full description

Bibliographic Details
Main Authors: Körner Christian, Riesner Katarina, Krämer Benjamin, Eisenhardt Marianne, Glässner Andreas, Wolter Franziska, Berg Thomas, Müller Tobias, Sauerbruch Tilman, Nattermann Jacob, Spengler Ulrich, Nischalke Hans
Format: Article
Language:English
Published: BMC 2012-03-01
Series:BMC Cancer
Subjects:
TRAIL receptor I
DR4
Apoptosis
Polymorphism
C626G (rs20575)
A683C (rs20576)
HCV
HCC
Cancer
Online Access:http://www.biomedcentral.com/1471-2407/12/85

Internet

http://www.biomedcentral.com/1471-2407/12/85

Similar Items